Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.
Conditions
- Carcinoma, Non-Small-Cell Lung
Interventions
- BIOLOGICAL: Tyrosine Kinase Inhibitor
- DRUG: Zoledronic Acid 4 MG/100 ML Intravenous Solution [ZOMETA]
- DRUG: Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
Sponsor
University of Colorado, Denver
Collaborators